Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,671
Stocks News & Analysis
stocks
Distribution growth for ASX income play
Cost containment and growing revenue bode well for profit margins.
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,284.20 | 51.60 | 0.56% |
| CAC 40 | 7,927.61 | 45.42 | -0.57% |
| DAX 40 | 24,223.76 | 53.21 | -0.22% |
| Dow JONES (US) | 44,938.31 | 16.04 | 0.04% |
| FTSE 100 | 9,271.84 | 16.30 | -0.18% |
| HKSE | 25,104.61 | 61.33 | -0.24% |
| NASDAQ | 21,172.86 | 142.09 | -0.67% |
| Nikkei 225 | 42,610.17 | 278.38 | -0.65% |
| NZX 50 Index | 13,194.07 | 122.77 | 0.94% |
| S&P 500 | 6,395.78 | 15.59 | -0.24% |
| S&P/ASX 200 | 9,019.10 | 45.40 | 0.51% |
| SSE Composite Index | 3,771.10 | 4.89 | 0.13% |